# OnCo record mavoric (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/mavoric/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "mavoric", "NCT01728805" ;
  schema:name "MAVORIC"@en ;
  schema:description "MAVORIC showed that mogamulizumab, an antibody that clears the malignant T cells that carry the CCR4 protein, kept cutaneous T-cell lymphoma under control for longer than the standard tablet vorinostat, and did especially well in the blood-involved Sezary form, which led to its approval."@en ;
  schema:url <https://onco.cc/trials/mavoric/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01728805> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/vorinostat/> ;
  onco:companies <https://onco.cc/companies/kyowa-kirin/> ;
  onco:people <https://onco.cc/people/youn-kim/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/> .